Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NovoCure Limited - Ordinary Shares (NQ:NVCR)

16.05 -0.89 (-5.28%)
Streaming Delayed Price Updated: 11:39 AM EDT, Apr 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NovoCure Limited - Ordinary Shares

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Better Mood Day
The US Treasury plans to require IRS reporting on US cryptocurrency trades of $10,000 and up to prevent tax evasion. 
Via Talk Markets
May Or May Not Happen
Another day, another drop. 
Via Talk Markets
Novocure Surges As FDA Allows A Six Months Shorter Lung Cancer Study
Novocure said Tuesday it could have the results of a pivotal lung cancer study six months sooner than expected, leading NVCR stock to pop. 
Via Investor's Business Daily
Exposures Product Safety
Novocure Gets FDA Approval For Reducing Sample Size For Late-Stage Pivotal LUNAR Lung Cancer Study
The FDA has approved Novocure Ltd's (NASDAQ: NVCR) Investigational Device Exemption (IDE) supplement, reducing the enrollment requirement for its LUNAR Phase 3... 
Via Benzinga
Exposures Product Safety
Recap: NovoCure Q1 Earnings
Shares of NovoCure (NASDAQ:NVCR) fell 2.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 200.00% year over... 
Via Benzinga
Earnings Scheduled For April 29, 2021
Companies Reporting Before The Bell • OSI Systems (NASDAQ:OSIS) is estimated to report quarterly earnings at $1.33 per share on revenue of $290.51 million. •... 
Via Benzinga
Novocure Announces FDA Approval of IDE Supplement for Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Friday Of The Heavy Week
There is nothing like a pending weekend to push Wall Street into recuperation and this worked today 
Via Talk Markets
Could Novocure Be a Millionaire-Maker Stock?
It's a good stock, but it might struggle to make you rich overnight. 
Via The Motley Fool
Heavy Global Erosion
It is an everything-down day. Even the news is down because commenters are being careful. 
Via Talk Markets
Gold Up Four Days In A Row
The dollar is at a nearly 3 month low. 
Via Talk Markets
Calm Markets Day
Despite seriously disappointing April jobless numbers, markets are gaining all the same. 
Via Talk Markets
Finns and Danes
Stock markets are still uncertain whether to rise or fall after the Tuesday debacle. 
Via Talk Markets
Cramer Weighs In On Penn National Gaming, Palantir And More
On CNBC's "Mad Money Lightning Round," Jim Cramer said he happens to like Penn National Gaming, Inc (NASDAQ: PENN) very much and it deserves to trade higher. Alcoa (... 
Via Benzinga
Unusually Heavy Friday
Today is a heavy news day, which is unusual for a Friday. We start with the largest company's lamentable report, follow with another confusing result, then a hopeful drug company report, and finish... 
Via Talk Markets
Is Novocure Stock Overvalued?
Did the market overreact to the company's good news? 
Via The Motley Fool
Another Heavy News Day
For whatever it is worth, markets seem keen on the proposed measures, boosted by a nicely lower level of new unemployment insurance claims last week. 
Via Talk Markets
Stock Market Rally Navigates Earnings From Apple, Tesla, Google, Facebook, Microsoft, Amazon
The stock market rally navigated earnings from Apple, Tesla and the other "big six" market cap companies. Many breakouts, but not all succeeded. 
Via Investor's Business Daily
NovoCure (NVCR) Q1 2021 Earnings Call Transcript
NVCR earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Novocure Reports Surprise Loss As Revenue Falls Short
Novocure reported a surprise loss as the cancer-fighting medtech missed on revenue. NVCR stock fell. 
Via Investor's Business Daily
The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ:... 
Via Benzinga
Novocure Reports First Quarter 2021 Financial Results and Provides Company Update
From Novocure
Via Business Wire
The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) Aldeyra Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
London Cancel
Brazilian Cosan is up 0.43% despite desperate Covid-19 outbreaks along the Amazon. 
Via Talk Markets
Exposures COVID-19
The Daily Biotech Pulse: Lilly, Novartis Trail Q1 Estimates, Exec Departure At Applied Genetics, Patent Award For Scholar Rock, Aldeyra Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 26) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Earth Day
Once again the exchanges are unsure if they want to go up or down. 
Via Talk Markets
The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx
Biopharma stocks came back from the weakness seen in the first two sessions to close the week ended April 23 higher. Johnson & Johnson (NYSE: JNJ) and Roche Holding AG (OTC:... 
Via Benzinga
Exposures Product Safety
Novocure Announces FDA IDE Approval and Steering Committee for KEYNOTE-B36 Trial Evaluating Tumor Treating Fields Together with Pembrolizumab in Non-Small Cell Lung Cancer
From Novocure
Via Business Wire
Cancer Therapy Novocure Stock Still On A High As It Clears Technical Benchmark
Cancer therapy Novocure stock had its Relative Strength (RS) Rating upgraded from 90 to 93 Wednesday. It's also an IBD 50 member. 
Via Investor's Business Daily
Is Novocure a Buy?
Once a stock goes up 50% in a single day, it can be hard to keep the momentum going. 
Via The Motley Fool
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.